Tracking ergothioneine in healthy volunteers

Editorial study summary

Study type

Double-blind randomized placebo-controlled uptake study

Product relevance

Relevant ingredient evidence; different formulation

Sample or population

45 healthy men aged 21–35; 15 per group

Studied dose

Ergothioneine 5 or 25 mg/day, or placebo

Duration

7-day dosing; follow-up through day 35

Finding

Blood ergothioneine increased and urinary loss was low. Most measured oxidative-damage/inflammation changes were not statistically significant.

Limitations

Short, small, male-only study; biomarkers rather than clinical outcomes. The 25 mg arm does not make this a trial of the DR.MORGAN spermidine–EGT combination.

Study quality

Original publisher methods, results and disclosures checked. No formal overall risk-of-bias rating assigned.

Funding and disclosures

Singapore NMRC funded the study. The original paper lists who provided the study materials and the authors’ disclosures. The authors reported no competing financial interests.

This research does not establish results for a DR.MORGAN finished product.

Reference

1. Cheah et al. · 2017 · PMID 27488221